Metabolic syndrome-related hyperuricemia is associated with a poorer prognosis in patients with colorectal cancer: A multicenter retrospective study
Cancer Management and Research Nov 26, 2021
Feng Q, Tang LJ, Luo DH, et al. - Metabolic syndrome (MetS)-related hyperuricemia holds prognostic importance on survival in colorectal cancer (CRC).
A correlation of hyperuricemia and MetS with the prognosis in malignant tumors has been reported.
A total of 1,271 patients who had undergone radical CRC resection were included and were preoperatively split into four groups: those with hyperuricemia alone (H), those with MetS alone (MS), those with MetS-related hyperuricemia (MSH), and those with neither condition (control [C] group).
Significant link between preoperative MetS and hyperuricemia was found.
In multivariate Cox regression analysis, MetS-related hyperuricemia (hazard ratio [HR] = 2.728) as well as MetS alone (HR = 1.631) were identified as independent predictors of death, whereas simple hyperuricemia was not.
Compared with the C group, the highest rate of tumor recurrence or metastasis was observed in the MSH group (HR = 5.103), followed by the MS (HR = 2.231) group.
There was a significant link of MetS with poor prognosis, with MetS-related hyperuricemia causing a significantly poorer prognosis.
In contrast, long-term prognosis remained unaffected by hyperuricemia alone.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries